139 results
8-K
EX-99.1
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E
8-K
EX-99.2
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
in China with our partner, Shanghai Fosun Pharmaceutical; constitute forward-looking statements within the meaning of the Private Securities Litigation
8-K
EX-1.1
RVNC
Revance Therapeutics Inc
5 Mar 24
Other Events
5:08pm
annual or interim period during the current or prior three fiscal years; or (iii) any Internal Control Event.
(cc) Litigation. Except as disclosed … , in case of any notice pursuant to Section 9(c) hereof, to the Director of Litigation, Office of the General Counsel, Barclays Capital Inc., 745 Seventh
424B5
e3rjrac il
5 Mar 24
Prospectus supplement for primary offering
5:00pm
424B5
v847co
4 Mar 24
Prospectus supplement for primary offering
6:39am
8-K
EX-10.2
jz0pk748lzfhi3gx5r
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-99.1
zbljzdssjm
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-10.1
i85dcd0urwau0ya ootd
13 Feb 24
Departure of Directors or Certain Officers
4:28pm
8-K
EX-99.1
zbz6c4y0dev1xiqx
8 Jan 24
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
8:01am
8-K
EX-99.1
gzicd
8 Nov 23
Provides Corporate Update
4:09pm
8-K
EX-99.2
cdrv2 gsffpofdj2bkkd
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
5j0ev5 0xk
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.1
3ehx5rg5n1l
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.1
eqqhfc64m3rtophj
8 Aug 23
Provides Corporate Update
4:08pm